Thermo Fisher Scientific and Daiichi Sankyo have expanded their partnership to co-develop a companion diagnostic (CDx) using Thermo Fisher’s next-gen sequencing (NGS)-based Oncomine Dx Target Test. The CDx will be designed to identify non-small cell lung cancer (NSCLC) patients with human epidermal growth factor receptor 2 (HER2) mutations who may be eligible for Enhertu, a HER2 directed antibody drug conjugate (ADC), currently in Phase II development for HER2 mutated or HER2 overexpressing NSCLC.
 
Enhertu has demonstrated a strong response rate in patients with HER2 positive metastatic breast cancer and preliminary results show a similar response in patients with metastatic NSCLC with HER2 mutations.

Thermo Fisher will retain rights to commercialize the test globally and will seek approval from regulatory agencies. In 2018 the companies partnered to expand the clinical utility of the test in support of Daiichi’s clinical trials and drug development programs.
 
The Oncomine Dx Target Test is the first targeted NGS in vitro diagnostic test approved by the U.S. FDA for NSCLC. It is designed to evaluate multiple biomarkers associated with cancer and identify patients who are eligible for multiple FDA-approved targeted therapies using a single sample with results available in days.
 
“Our latest partnership with Daiichi Sankyo is focused on helping to solve an unmet medical need for a growing number of patients with HER2-mutated non-small cell lung cancer,” said Garret Hampton, president of clinical next-generation sequencing and oncology at Thermo Fisher Scientific. “This agreement underscores our continued commitment to working with global pharmaceutical partners to efficiently identify more patients who may benefit from the latest targeted therapies in their drug pipelines.”